Quest Diagnostics Reports Second Quarter 2025 Financial Results

Quest Diagnostics Incorporated, a leading provider of diagnostic information services, has released its financial results for the second quarter ended June 30, 2025. The company reported significant growth in revenues and earnings, prompting an upward revision of its full-year guidance for 2025.

Financial Highlights

For the second quarter of 2025, Quest Diagnostics reported revenues of $2.76 billion, marking a 15.2% increase from the same period in 2024. The company's reported diluted earnings per share (EPS) rose by 21.7% to $2.47, while adjusted diluted EPS increased by 11.5% to $2.62. Year-to-date cash provided by operations reached $858 million, a substantial 67.1% increase from the previous year.

Business and Operational Highlights

The company's growth was driven by a combination of organic revenue growth, increased demand for innovative clinical solutions, and expanded business from enterprise accounts. Additionally, productivity gains were realized through the deployment of automation and digital technologies across operations.

Strategic Initiatives and Corporate Developments

Quest Diagnostics has been actively involved in acquisitions, which have contributed to its revenue growth. The company also reported a significant increase in cash provided by operations and capital expenditures, reflecting its ongoing investments in business expansion and technological advancements.

Management's Perspective

Jim Davis, Chairman, CEO, and President of Quest Diagnostics, commented on the strong performance, stating, "Through continued execution of our strategy, we delivered a strong second quarter, with revenues growing 15.2% which includes 5.2% from organic revenues, as well as adjusted EPS growth of 11.5%. Demand for our innovative clinical solutions and expanded business from enterprise accounts complemented growth from acquisitions. We also realized productivity gains as we continued to deploy automation and digital technologies across our operations. Given our performance in the quarter and continued utilization trends, we are raising our full year 2025 guidance."

Future Outlook

Quest Diagnostics has updated its full-year 2025 guidance, now expecting reported diluted EPS to be between $8.60 and $8.80, and adjusted diluted EPS to be between $9.63 and $9.83. The company also anticipates net revenues to range from $10.80 billion to $10.92 billion, reflecting a 9.4% to 10.6% increase from the previous year.

SEC Filing: QUEST DIAGNOSTICS INC [ DGX ] - 8-K - Jul. 22, 2025